2024
Intravenous Infusion of Autologous Mesenchymal Stem Cells Expanded in Auto Serum for Chronic Spinal Cord Injury Patients: A Case Series
Hirota R, Sasaki M, Iyama S, Kurihara K, Fukushi R, Obara H, Oshigiri T, Morita T, Nakazaki M, Namioka T, Namioka A, Onodera R, Kataoka-Sasaki Y, Oka S, Takemura M, Ukai R, Yokoyama T, Sasaki Y, Yamashita T, Kobayashi M, Okuma Y, Kondo R, Aichi R, Ohmatsu S, Kawashima N, Ito Y, Kobune M, Takada K, Ishiai S, Ogata T, Teramoto A, Yamashita T, Kocsis J, Honmou O. Intravenous Infusion of Autologous Mesenchymal Stem Cells Expanded in Auto Serum for Chronic Spinal Cord Injury Patients: A Case Series. Journal Of Clinical Medicine 2024, 13: 6072. PMID: 39458022, PMCID: PMC11509003, DOI: 10.3390/jcm13206072.Peer-Reviewed Original ResearchAmerican Spinal Injury Association Impairment ScaleSevere spinal cord injuryMesenchymal stem cell infusionAutologous mesenchymal stem cellsIntravenous infusionCase seriesMesenchymal stem cellsQuality of lifeAuto-serumSpinal cord injuryFunctional improvementChronic spinal cord injury patientsIntravenous infusion of mesenchymal stem cellsInfusion of mesenchymal stem cellsStem cellsCord injurySpinal Cord Independence Measure IIIAmerican Spinal Injury Association Impairment Scale grades CSpinal cord injury patientsChronic SCI patientsClassification of Spinal Cord InjuryNeurological Classification of Spinal Cord InjurySignificant functional improvementAssociation Impairment ScaleInternational Standards for Neurological Classification of Spinal Cord InjuryIntravenous infusion of auto-serum-expanded autologous mesenchymal stem cells into chronic severe brain injury patients
Yamaki T, Oka S, Iyama S, Sasaki M, Onodera R, Kataoka-Sasaki Y, Namioka T, Namioka A, Nakazaki M, Takemura M, Ukai R, Yokoyama T, Sasaki Y, Yamashita T, Kobayashi M, Yamaguchi M, Fukino M, Takazawa T, Hayasaka M, Owaku T, Funakura M, Onodera S, Ito Y, Kobune M, Kato J, Ishiai S, Kocsis J, Odaki M, Iwadate Y, Kobayashi S, Honmou O. Intravenous infusion of auto-serum-expanded autologous mesenchymal stem cells into chronic severe brain injury patients. Interdisciplinary Neurosurgery 2024, 36: 101927. DOI: 10.1016/j.inat.2023.101927.Peer-Reviewed Original ResearchSevere brain injury patientsAutologous mesenchymal stem cellsBrain injury patientsIntravenous infusionMesenchymal stem cellsAdverse eventsInjury patientsInfused mesenchymal stem cellsHealth Stroke ScaleSerious adverse eventsFugl-Meyer AssessmentInitial case seriesBrain metabolic activityStem cellsMSC infusionStroke ScaleNeurological deteriorationBarthel IndexCase seriesCNS tumorsNeurological functionFunctional statusFunctional improvementChronic patientsPlacebo effect
2022
Intravenous Infusion of Autoserum-Expanded Autologous Mesenchymal Stem Cells in Patients With Chronic Brain Injury: Protocol for a Phase 2 Trial
Oka S, Yamaki T, Sasaki M, Ukai R, Takemura M, Yokoyama T, Kataoka-Sasaki Y, Onodera R, Ito YM, Kobayashi S, Kocsis JD, Iwadate Y, Honmou O. Intravenous Infusion of Autoserum-Expanded Autologous Mesenchymal Stem Cells in Patients With Chronic Brain Injury: Protocol for a Phase 2 Trial. JMIR Research Protocols 2022, 11: e37898. PMID: 35793128, PMCID: PMC9301565, DOI: 10.2196/37898.Peer-Reviewed Original ResearchChronic brain injuryAutologous mesenchymal stem cellsSpinal cord injuryINTERNATIONAL REGISTERED REPORT IDENTIFIERBrain injuryIntravenous infusionRankin Scale gradesCord injuryMesenchymal stem cellsClinical trialsScale gradeTherapeutic efficacyJapan Medical Association CenterSapporo Medical University HospitalInvestigator-initiated clinical trialsModified Rankin Scale gradesOpen-label trialPhase 2 studyPhase 2 trialMedical University HospitalCause of disabilityMotor vehicle accidentsPotential therapeutic efficacyProportion of casesStem cells